Benzamide inhibitors of the P2X
View Patent ↗The present invention provides benzamide inhibitors of the P2X 7 receptor of the formula: wherein R 1 -R 3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
1. A compound of the formula
wherein R 1 is methyl or ethyl optionally substituted with one or two groups independently selected from hydroxyl, (C 6 -C 7 )cycloalkyl and phenyl; wherein said (C 6 -C 7 )cycloalkyl and phenyl may be optionally substituted by one to three radicals independently selected from hydroxyl, halo, methyl and phenyl;
R 2 is halo;
R 3 is an optionally substituted carbon linked 6-membered heteroaryl or heterocyclyl group selected from the group of:
wherein R 4 is independently selected from the group consisting of hydrogen, methyl and (C 1 -C 6 )alkoxy;
wherein the molecular weight of said compound of formula I is less than 700 AMU; or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1 selected from the group of:
2-Chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-(6-oxo-1,6-dihydro-pyrazin-3-yl)benzamide;
2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-(6-oxo-1,6-dihydro-pyridazin-3-yl)benzamide;
2-Chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-(5-methyl-pyridin-2-yl)-benzamide;
2-Chloro-5-(6-methyl-pyridin-3-yl)-N-(1-p-tolyl-cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-3,3-dimethyl-cyclohexylmethyl)-5-(5-methyl-pyridin-2-yl)-benzamide;
2-Chloro-N-(1hydroxy-cycloheptylmethyl)-5-(5-methyl-pyridin-2-yl)-benzamide;
2-Chloro-N-(1hydroxy cycloheptylmethyl)5(6methoxy-pyridazin-3-yl)-benzamide;
2-Chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-(6-methoxy-pyridazin-3-yl)-benzamide;
2-Chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-(2-methyl-pyrimidin-4-yl)-benzamide;
2-Chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-[1-(2-hydroxy-ethyl)-6-oxo-1,6-dihydro-pyridazin-3-yl]-benzamide; and
2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[1-(2-hydroxy-ethyl)-6-oxo-1,6-dihydro-pyridazin-3-yl]-benzamide; or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.